Edition:
United States

Trevena Inc (TRVN.OQ)

TRVN.OQ on NASDAQ Stock Exchange Global Select Market

1.66USD
1:14pm EST
Change (% chg)

$0.14 (+9.54%)
Prev Close
$1.52
Open
$1.51
Day's High
$1.69
Day's Low
$1.51
Volume
124,857
Avg. Vol
141,907
52-wk High
$8.00
52-wk Low
$1.35

Chart for

About

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in... (more)

Overall

Beta: -0.59
Market Cap(Mil.): $90.74
Shares Outstanding(Mil.): 59.70
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Trevena Inc says Q3 loss per share $0.27

* Trevena reports third quarter 2017 financial results and announces new positive clinical trial data

Nov 07 2017

BRIEF-Trevena announces submission of NDA to U.S. FDA for Olinvo

* Trevena announces submission of new drug application to U.S. FDA for Olinvo (oliceridine injection)

Nov 02 2017

BRIEF-‍trevena announces publication and presentations of olinvo clinical data​

* ‍Trevena announces publication and presentations of olinvo (oliceridine injection) clinical data​ Source text for Eikon: Further company coverage:

Oct 25 2017

BRIEF-Trevena announces restructuring to focus resources on commercial strategy

* Trevena announces restructuring to focus resources on commercial strategy

Oct 11 2017

Earnings vs. Estimates